NanoViricides Restructures Agreements to Alleviate Financial Stress
EF Hutton Reiterates Buy on Nanoviricides, Maintains $6.5 Price Target
EF Hutton analyst Tim Moore reiterates Nanoviricides (AMEX:NNVC) with a Buy and maintains $6.5 price target.
Nanoviricides Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/16/2024 470.18% EF Hutton → $6.5 Reiterates Buy → Buy 06/01/2023 360.53% EF Hutton → $5.25 Assumes → Bu
Nanoviricides Q2 EPS $(0.18) Down From $(0.15) YoY; As Of December 31, 2023, We Had Cash And Cash Equivalent Current Assets Balance Of Approximately $5.31M. Additional Agreements Have Resulted In A Further Approximately $2.5M Available Cash
Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.18) per share. This is a 20 percent decrease over losses of $(0.15) per share from the same period last year.
NanoViricides GAAP EPS of -$0.18
NanoViricides Reports Positive Safety Results for COVID Drug Candidate
NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
NanoViricides Updates Progress on Phase 1a/1b Clinical Trial of Antiviral Drug Candidate NV-387
NanoViricides Has Completed The Single-ascending Dose Part Of The Phase 1A/1B Human Trial Of NV-COV-2, A Broad-spectrum Antiviral Drug, Recruitment For The Multiple-ascending Dose Part Was Also Completed
NanoViricides Has Completed The Single-ascending Dose Part Of The Phase 1A/1B Human Trial Of NV-COV-2, A Broad-spectrum Antiviral Drug, Recruitment For The Multiple-ascending Dose Part Was Also Comple
NanoViricides Shares Rise On Successful Results Of Phase 1a/1b Human Clinical Trial Of NV-CoV-2
Nanoviricides Reported That The Phase 1a/1b Human Clinical Trial Of NV-CoV-2, The Company's Broad-spectrum Antiviral Drug, Is Progressing Successfully
The Company reports that its Indian collaborator and drug sponsor, Karveer Meditech Pvt. Ltd., India, has communicated that approximately 26 out of the target of 36 healthy volunteers in the various c
Healthcare Triangle, Recursion Top Healthcare Gainers; PainReform, Biodexa Among Losers
RDFN, YELL and NNVC Among Pre-market Losers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersAdial Pharmaceuticals (NASDAQ:ADIL) stock increased by 114.8% to $0.43 during Tuesday's regular session. The current volume of 86.1 million shares is 45600.6% of Adial Pharmaceuticals's average
RDFN, SOS and BDRX Among Mid-day Movers
Why Are NanoViricides Shares Gaining Today
NanoViricides Inc (NYSE:NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical drug candidate for Respiratory Syncytial Virus (RSV). The company reporte
NanoViricides Shares Surge on NV-387 Showing in RSV >NNVC
By Colin Kellaher NanoViricides shares jumped more than 25% on Tuesday after the clinical-stage company said its broad-spectrum antiviral clinical drug candidate NV-387 showed effectiveness in an ani
Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness In RSV In A Lethal Lung Disease Animal Model, Reports NanoViricides
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV (Respiratory Syncytial Virus).
NanoViricides Reports Effectiveness Of Antiviral Clinical Drug Candidate NV-387 In An Animal Model Of Lethal Lung Infection With Respiratory Syncytial Virus
NanoViricides Reports Effectiveness Of Antiviral Clinical Drug Candidate NV-387 In An Animal Model Of Lethal Lung Infection With Respiratory Syncytial Virus
NanoViricides Says Clinical Trial Of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Satisfactorily
Following safety and tolerability evaluation in healthy persons for a single escalating dose of NV-CoV-2 Oral Syrup or NV-CoV-2 Oral Gummies in the Part 1a, the clinical trial will continue into Part
No Data